509 related articles for article (PubMed ID: 28241851)
1. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries.
Gerbens LA; Boyce AE; Wall D; Barbarot S; de Booij RJ; Deleuran M; Middelkamp-Hup MA; Roberts A; Vestergaard C; Weidinger S; Apfelbacher CJ; Irvine AD; Schmitt J; Williamson PR; Spuls PI; Flohr C
Trials; 2017 Feb; 18(1):87. PubMed ID: 28241851
[TBL] [Abstract][Full Text] [Related]
2. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries.
Gerbens LAA; Apfelbacher CJ; Irvine AD; Barbarot S; de Booij RJ; Boyce AE; Deleuran M; Eichenfield LF; Hof MH; Middelkamp-Hup MA; Roberts A; Schmitt J; Vestergaard C; Wall D; Weidinger S; Williamson PR; Flohr C; Spuls PI;
Br J Dermatol; 2019 Apr; 180(4):790-801. PubMed ID: 29761486
[TBL] [Abstract][Full Text] [Related]
3. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries.
Vermeulen FM; Gerbens LAA; Bosma AL; Apfelbacher CJ; Irvine AD; Arents BWM; Barbarot S; Deleuran M; Eichenfield LF; Manca A; Schmitt J; Vestergaard C; Wall D; Weidinger S; Middelkamp-Hup MA; Spuls PI; Flohr C;
Br J Dermatol; 2019 Sep; 181(3):492-504. PubMed ID: 30719709
[TBL] [Abstract][Full Text] [Related]
4. A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS).
Wall D; Meah N; York K; Bhoyrul B; Bokhari L; Abraham LS; Adams R; Bergfeld W; Betz RC; Blume-Peytavi U; Callender V; Campbell C; Chambers J; Chen G; Chitreddy V; Cotsarelis G; Craiglow B; Dhurat R; Dlova N; Donovan J; Duque-Estrada B; Eisman S; Ellison A; Farrant P; Barberá JF; Gadzhigoroeva A; Grimalt R; Harries M; Hordinsky M; Irvine AD; Jolliffe V; Jones L; King B; Lee WS; Lortkipanidze N; McMichael A; Messenger A; Mirmirani P; Olsen E; Orlow SJ; Ovcharenko Y; Piraccini BM; Pirmez R; Rakowska A; Reygagne P; Riley M; Rudnicka L; Saceda Corralo D; Shapiro J; Sharma P; Silyuk T; Kaiumov S; Tobin DJ; Tosti A; Vañó-Galván S; Vogt A; Wade M; Yip L; Zlotogorski A; Zhou C; Sinclair R
JAMA Dermatol; 2021 Apr; 157(4):1-11. PubMed ID: 33656556
[TBL] [Abstract][Full Text] [Related]
5. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries.
Spuls PI; Gerbens LAA; Apfelbacher CJ; Wall D; Arents BWM; Barbarot S; Roberts A; Deleuran M; Middelkamp-Hup MA; Vestergaard C; Weidinger S; Schmitt J; Irvine AD; Flohr C
J Invest Dermatol; 2017 Sep; 137(9):2014-2016. PubMed ID: 28558913
[No Abstract] [Full Text] [Related]
6. Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce.
Bosma AL; Musters AH; Bloem M; Gerbens LAA; Middelkamp-Hup MA; Haufe E; Schmitt J; Barbarot S; Seneschal J; Staumont-Sallé D; Johansson EK; Bradley M; von Kobyletzki LB; Vittrup I; Frier Ruge I; Thyssen JP; Vestergaard C; de Vega M; García-Doval I; Chiricozzi A; Stingeni L; Calzavara-Pinton P; Ardern-Jones MR; Reynolds NJ; Flohr C; Spuls PI
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):123-136. PubMed ID: 36018221
[TBL] [Abstract][Full Text] [Related]
7. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.
Bosma AL; Spuls PI; Garcia-Doval I; Naldi L; Prieto-Merino D; Tesch F; Apfelbacher CJ; Arents BWM; Barbarot S; Baselga E; Deleuran M; Eichenfield LF; Gerbens LAA; Irvine AD; Manca A; Mendes-Bastos P; Middelkamp-Hup MA; Roberts A; Seneschal J; Svensson Å; Thyssen JP; Torres T; Vermeulen FM; Vestergaard C; von Kobyletzki LB; Wall D; Weidinger S; Schmitt J; Flohr C
Br J Dermatol; 2020 Jun; 182(6):1423-1429. PubMed ID: 31444799
[TBL] [Abstract][Full Text] [Related]
8. Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies.
De Bruin-Weller M; Biedermann T; Bissonnette R; Deleuran M; Foley P; Girolomoni G; Hercogová J; Hong CH; Katoh N; Pink AE; Richard MA; Shumack S; Silvestre JF; Weidinger S
Acta Derm Venereol; 2021 Feb; 101(2):adv00402. PubMed ID: 33491094
[TBL] [Abstract][Full Text] [Related]
9. Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice.
van Geel N; Hamzavi IH; Pandya AG; Wolkerstorfer A; Seneschal J; Garg A; Spuls P; Terwee CB; Mallett S; Speeckaert R; Meurant JM; Eleftheriadou V; Ezzedine K
Trials; 2022 Jul; 23(1):591. PubMed ID: 35871019
[TBL] [Abstract][Full Text] [Related]
10. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas KS; Apfelbacher CA; Chalmers JR; Simpson E; Spuls PI; Gerbens LAA; Williams HC; Schmitt J; Gabes M; Howells L; Stuart BL; Grinich E; Pawlitschek T; Burton T; Howie L; Gadkari A; Eckert L; Ebata T; Boers M; Saeki H; Nakahara T; Katoh N
Br J Dermatol; 2021 Jul; 185(1):139-146. PubMed ID: 33393074
[TBL] [Abstract][Full Text] [Related]
11. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.
Schmitt J; Spuls PI; Thomas KS; Simpson E; Furue M; Deckert S; Dohil M; Apfelbacher C; Singh JA; Chalmers J; Williams HC;
J Allergy Clin Immunol; 2014 Oct; 134(4):800-7. PubMed ID: 25282560
[TBL] [Abstract][Full Text] [Related]
12. Three nested randomized controlled trials of peer-only or multiple stakeholder group feedback within Delphi surveys during core outcome and information set development.
Brookes ST; Macefield RC; Williamson PR; McNair AG; Potter S; Blencowe NS; Strong S; Blazeby JM
Trials; 2016 Aug; 17(1):409. PubMed ID: 27534622
[TBL] [Abstract][Full Text] [Related]
13. COSUMO: study protocol for the development of a core outcome set for efficacy and effectiveness trials in posterior segment-involving uveitis.
Tallouzi MO; Mathers JM; Moore DJ; Murray PI; Bucknall N; Blazeby JM; Calvert M; Denniston AK
Trials; 2017 Dec; 18(1):576. PubMed ID: 29191216
[TBL] [Abstract][Full Text] [Related]
14. Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.
Callis Duffin K; Merola JF; Christensen R; Latella J; Garg A; Gottlieb AB; Armstrong AW
JAMA Dermatol; 2018 Oct; 154(10):1137-1144. PubMed ID: 29874367
[TBL] [Abstract][Full Text] [Related]
15. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema.
Vermeulen FM; Gerbens LAA; Schmitt J; Deleuran M; Irvine AD; Logan K; Ouwerkerk W; Vestergaard C; Flohr C; Spuls PI;
Br J Dermatol; 2020 Dec; 183(6):1073-1082. PubMed ID: 32068893
[TBL] [Abstract][Full Text] [Related]
16. Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
Schlessinger DI; Iyengar S; Yanes AF; Lazaroff JM; Godinez-Puig V; Chen BR; Kurta AO; Henley JK; Chiren SG; Furlan KC; Schmitt J; Deckert S; Poon E; Sobanko JF; Cartee TV; Alam M; Maher IA
Trials; 2017 Oct; 18(1):490. PubMed ID: 29061190
[TBL] [Abstract][Full Text] [Related]
17. Chinese herbal medicine granules (PTQX) for children with moderate to severe atopic eczema: study protocol for a randomised controlled trial.
Gu SX; Zhang AL; Coyle ME; Mo X; Lenon GB; Cranswick NE; Chen D; Xue CC
Trials; 2015 Jul; 16():294. PubMed ID: 26149448
[TBL] [Abstract][Full Text] [Related]
18. Generic outcome set for the international registry on Laser trEAtments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on
Fransen F; Spuls P; Alam M; Badawi A; Boixeda P; Haedersdal M; Hamzavi I; Hedelund L; Kelly KM; Kono T; Laubach HJ; Manuskiatti W; Marini L; Nouri K; Paasch U; Passeron T; Prinsen CACS; Verner I; Wolkerstorfer A
BMJ Open; 2020 Jun; 10(6):e038145. PubMed ID: 32595165
[TBL] [Abstract][Full Text] [Related]
19. A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative.
Jacobson ME; Rick JW; Gerbens LAA; Baghoomian W; Gould LJ; Marzano AV; Chen DM; Oakes DL; Dissemond J; Yamamoto T; Shinkai K; Nolan B; Lobato D; Thomas KS; Ortega-Loayza AG;
Br J Dermatol; 2024 Feb; 190(3):392-401. PubMed ID: 37952167
[TBL] [Abstract][Full Text] [Related]
20. Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE).
Healy P; Gordijn S; Ganzevoort W; Beune I; Baschat A; Khalil A; Kenny L; Bloomfield F; Daly M; Papageorghiou A; Devane D
Trials; 2018 Aug; 19(1):451. PubMed ID: 30134949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
